Previous 10 | Next 10 |
Xeris Pharmaceuticals (NASDAQ: XERS ): Q1 GAAP EPS of -$0.89 misses by $0.05 . More news on: Xeris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Gvoke™ Pre-Filled Syringe (PFS) net sales of $1.7 million in Q1 2020 Gvoke HypoPen™ on track for planned launch in July 2020 Initiated programs to ensure easier patient access to GVOKE in the midst of the COVID-19 pandemic Corporate actions taken to conserve ca...
Xeris Pharmaceuticals (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, recently announced that it will release its first quarter 2020 financial results ...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its first quarte...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it has extended its $0 copay offer for Gvoke™ Pre-F...
Nano cap Xeris Pharmaceuticals (NASDAQ: XERS ) is up 19% premarket on light volume in reaction to results from a Phase 1b study assessing two dose levels of its injectable formulation of diazepam in 20 healthy volunteers. More news on: Xeris Pharmaceuticals, Inc., Healthcare ...
Xeris’ IM diazepam maintains higher concentration over longer time period versus standard of care Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and commercialize ready-to-use injectable and in...
Xeris Pharmaceuticals Inc. (NASDAQ: XERS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $18PT. Our assumptions include: Launch of the glucagon re...
Gainers: Camber Energy (NYSEMKT: CEI ) +61% . More news on: Camber Energy, Inc., Cancer Genetics, Inc., Micron Solutions, Inc., Stocks on the move, , Read more ...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced a limited-time $0 copay offering for commercially eligible...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...